Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 248

Results For "IND"

6319 News Found

Zydus receives USFDA’s final approval for Valsartan Tablets
Drug Approval | July 24, 2024

Zydus receives USFDA’s final approval for Valsartan Tablets

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India


USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau
Drug Approval | July 24, 2024

USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau

The inspections concluded with no Form 483 observations or significant critical findings


Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution
Drug Approval | July 24, 2024

Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug


Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
Drug Approval | July 24, 2024

Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH

Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)


Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr
News | July 24, 2024

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores


Caplin Steriles gets USFDA approval for Ephedrine Sulfate injection USP
Drug Approval | July 23, 2024

Caplin Steriles gets USFDA approval for Ephedrine Sulfate injection USP

Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension


Biolyst Scientific announced as new brand name to encompass EMS and Azer
News | July 23, 2024

Biolyst Scientific announced as new brand name to encompass EMS and Azer

The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas


Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC
Clinical Trials | July 23, 2024

Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT